The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Supplement use in MGUS, smoldering myeloma, and multiple myeloma: findings from a patient survey
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses findings from a patient survey on supplement uptake in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, and multiple myeloma. The survey focused on omega-3, vitamin D, probiotics, and curcumin, and showed increased use, particularly of curcumin and omega-3, following diagnosis in patients with MGUS and smoldering myeloma. Dr Shah explains that vitamin D supplementation likely has the strongest supporting evidence, but around a third of patients are unaware of their vitamin D levels, and no randomized trials have been conducted. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
